[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"end-stage-kidney-disease-esrd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:end-stage-kidney-disease-esrd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,50,81,119,145,173,194,217,247,283,317,342],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100652936","phase-3-strategies-for-the-management-of-atrial-fibrillation-in-patients-receiving-dialysis-2-safe-d2-100652936",false,"NCT07779746","Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)","SAFE-D2","Inclusion criteria\n\nTo be eligible to participate in this trial, participants need to satisfy ALL these inclusion criteria:\n\n1. Age ≥18 years,\n2. Kidney failure treated with hemodialysis or peritoneal dialysis for at least 90 days,\n3. A history of non-valvular AF or atrial flutter (AFL) defined as one of the following:\n\n   1. AF\u002FAFL on an ECG at enrollment.\n   2. ≥2 episodes of AF\u002FAFL on cardiac diagnostics with each episode lasting ≥30 seconds and occurring ≥24 hours apart.\n   3. One episode of AF\u002FAFL on cardiac diagnostics lasting ≥30 seconds, plus ≥1 separate documented episode in the medical record.\n   4. One episode of AF (reported by cardiac diagnostics or documented in the medical record) plus treatment with an oral anticoagulant for stroke prevention as a result of AF\u002FAFL; or\n   5. AF\u002FAFL documented on one occasion in a cardiologist report.\n4. Meet the CHA2DS2-VASc criteria (i.e. ≥2 for men and ≥3 for women)\n\nExclusion Criteria\n\nPotential participants must have NONE of the following exclusion criteria:\n\n1. Mitral stenosis described as moderate or severe.\n2. Anticoagulation indicated for a reason other than atrial fibrillation.\n3. Receipt of aspirin at a dose of \\>160 mg daily.\n4. Ongoing requirement at screening for a strong CYP3A4\u002FP-gp inhibitor or inducer that cannot be discontinued, substituted, or otherwise managed safely.\n5. Ongoing requirement for dual antiplatelet therapy at the time of screening that, in the judgement of the treating clinician, is expected to remain necessary after randomization and cannot be safely de-escalated to single antiplatelet therapy in the event of randomization to apixaban.\n6. Known clinically significant coagulopathy, or other bleeding risk that, in the judgment of the treating physician, renders oral anticoagulation unsafe.\n7. A major bleeding event in the 30 days prior to study enrollment, or any active and clinically significant bleeding.\n8. Current pregnancy or breastfeeding.\n9. Anticipated life expectancy \\\u003C 6 months.\n10. A scheduled live donor kidney transplant in the next 6 months.\n11. Co-enrollment in a clinical trial where the intervention is deemed to interfere with the adherence, safety or efficacy of the SAFE-D2 treatment strategies\n12. The treating clinical team has determined that long-term OAC is clearly indicated such that randomization to the no OAC strategy would not be clinically acceptable.\n13. The treating clinical team has determined that long-term OAC is clearly contraindicated such that randomization to the apixaban strategy would not be clinically acceptable.","ALL","18 Years",{"count":19,"type":20},848,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","People receiving dialysis are more likely to develop atrial fibrillation (AF), an irregular heartbeat that increases the risk of stroke. Blood-thinning medications (anticoagulants) are commonly used to prevent strokes in people with AF, but it is not known whether they are beneficial for people receiving dialysis because this group has not been well represented in previous clinical trials. As a result, healthcare providers do not have clear evidence to guide treatment decisions.\n\nThe SAFE-D2 study will compare two approaches to preventing stroke in adults receiving maintenance hemodialysis or peritoneal dialysis who have non-valvular AF and are at increased risk of stroke. Participants will be randomly assigned (by chance) to receive either apixaban, an oral blood thinner, or no oral anticoagulant, while continuing to receive their usual dialysis and medical care.\n\nThe main goal of the study is to determine whether apixaban is more effective than no oral anticoagulant at reducing the risk of stroke or blood clots traveling to other parts of the body (systemic embolism). The study will also compare the two approaches with respect to survival, heart-related complications, major bleeding and other bleeding events, hospitalizations, dialysis access complications, quality of life, and the overall balance of benefits and risks.\n\nApproximately 848 participants from Canada, Brazil, and Israel will take part in the study. The results of SAFE-D2 are expected to provide important evidence to help patients, families, and healthcare providers make informed decisions about stroke prevention for people receiving dialysis who have atrial fibrillation.",[26,27,28,29],"Atrial Fibrillation","Atrial Flutter","End Stage Kidney Disease (ESRD)","Dialysis Patients",[31,32,33,34,35,36,37],"atrial fibrillation","end stage renal disease","end stage kidney disease","dialysis","oral anticoagulation","apixaban","no oral anticoagulation","NOT_YET_RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":20},"2026-11",{"date":46,"type":20},"2032-11",{"name":48,"class":49},"Unity Health Toronto","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100627322","prospective-analysis-of-arteriovenous-access-ava-use-in-continuous-renal-replacement-therapy-a-feasibility-project-100627322","NCT07447128","Prospective Analysis of Arteriovenous Access (AVA) Use in Continuous Renal Replacement Therapy: A Feasibility Project","Prospective Analysis of Arteriovenous Access Use in Continuous Renal Replacement Therapy, a Feasibility Project","CRRT","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. ESKD patients on chronic hemodialysis for \\>1 year in duration who are admitted to the ICU and in need of CRRT.\n3. Anticipated CRRT duration ≥24 hours, based on clinical assessment of the renal trajectory.\n4. Patient with functioning arteriovenous access, either arteriovenous fistula or arteriovenous graft.\n5. Expected mechanical ventilation for a minimum of 12 hours, based on clinical assessment of the underlying diagnosis.\n6. Expected Richmond Agitation Sedation Scale (RASS) goal of 0 or less for a minimum of 12 hours, based on clinical assessment of the underlying diagnosis.\n7. Patients able to tolerate placement of an arm board at the vascular access site.\n8. Baseline AVA blood flow of at least 600 mL\u002Fmin for AVG and 500 mL\u002Fmin for AVF during ultrasonography evaluation upon enrollment.\n\nExclusion Criteria:\n\n1. Age less than 18 years old.\n2. Patients who receive dialysis via hemodialysis catheter or existing central catheter suitable for hemodialysis.\n3. ESKD patients who, at the time of enrollment, have a sacral pressure ulcer or other clinically significant skin integrity impairment requiring frequent repositioning, extensive patient rotation, or advanced wound care management.\n4. Patients with elevated INR above 5 at the time of study enrollment.\n5. Patients with acute liver failure, defined as AST \\>1000 U\u002FL and\u002For ALT \\>1000 U\u002FL at the time of study enrollment.\n6. Patients with a platelet count of less than 50,000 (10⁹ plt\u002FL) at the time of study enrollment.\n7. Patients with evidence of disseminated intravascular coagulation at the time of study enrollment.\n8. Known pregnancy at the time of study enrollment.\n9. Patients at high risk for rapid clinical deterioration, or those deemed unsuitable for AVA-based CRRT by the prescribing nephrologist or ICU physician.",{"count":59,"type":20},50,[61],"NA","This study will test whether patients who already have a permanent dialysis access (an arteriovenous fistula or graft) can safely use that access for continuous dialysis (CRRT) while they are critically ill in the intensive care unit, instead of requiring a temporary central venous catheter. About 50 patients will participate. Researchers will monitor how well the access works, whether any complications occur, and whether there are differences between fistulas and grafts. The goal is to determine whether using a patient's existing dialysis access is a safe and practical option that could reduce the need for temporary catheters and their associated risks, such as infection and bleeding.",[64,28],"Continuous Renal Replacement Therapy (CRRT)",[66,67,56,68,69,70],"Arteriovenous access","Continuous Renal Replacement Therapy","AVA","ESKD","End Stage Kidney Disease","2026-07-01",{"date":73,"type":42},"2026-07-06",{"date":75,"type":20},"2026-07-27",{"date":77,"type":20},"2027-12-31",{"name":79,"class":49},"East Carolina University",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":99,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100644867","euvolemia-based-assessment-of-pulmonary-hypertension-in-stable-hemodialysis-patients-100644867","NCT07676786","Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients","Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis","EU-PHASE-HD","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* End-stage kidney disease on maintenance HD for ≥ 3 months.\n* Stable clinical condition (no hospitalization in last 30 days).\n* Able and willing to comply with study protocol.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Moderate\u002Fsevere left-sided valvular disease.\n* Active pulmonary or cardiac decompensation.\n* Persistent hypervolemia after completion of the volume assessment and correction phase\n* Inability to undergo echocardiography or bioimpedance assessment.\n* Acute infection or inflammatory condition at the time of enrollment.\n* Inadequate echocardiographic window preventing reliable assessment",{"count":90,"type":20},30,"OBSERVATIONAL","Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.\n\nThis prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.\n\nIn participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.\n\nThe study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.",[94,28,95,96,97,98],"Pulmonary Hypertension (PH)","Hemodialysis Patients","Volume Overload","Volume Assessment","Hemodialysis",[100,98,101,102,96,103,104,105,106,107,108,109],"Pulmonary Hypertension","End-Stage Kidney Disease","Euvolemia","Volume Status","Echocardiography","Bioimpedance Spectroscopy","Interdialytic Weight Gain","Vascular Access","Blood Pressure Variability","Lung Ultrasound","2026-06-24",{"date":112,"type":42},"2026-06-30",{"date":71,"type":20},{"date":115,"type":20},"2027-03-30",{"name":117,"class":49},"Stefan Lujinschi",2,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":118},"100609167","effect-of-the-amplifi-vein-dilation-system-on-outflow-vein-dilation-and-av-fistula-maturation-amplifi-1-100609167","NCT07211035","Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)","A Pivotal Study to Evaluate the Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and Arteriovenous Fistula Maturation","AMPLIFI-1","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Indicated for wrist or distal forearm radiocephalic AVF creation based on Investigator's standard practice\n3. End-Stage Renal Disease (ESRD) receiving maintenance hemodialysis.\n4. Baseline cephalic vein diameter between \\>1.7 mm and \\\u003C3.2 mm at the proposed Study AVF creation site in the distal forearm, with a continuous distal segment or tributary suitable for Amplifi System Outflow Catheter placement, including:\n\n   * A forearm cephalic vein segment of ≥ 14 cm in length that provides an approximately 10 cm cannulation zone, free of detectable occlusions or stenosis, with collaterals.\n   * Central continuity of the forearm cephalic vein at the elbow demonstrated through one or any combination of the following pathways:\n\n     1. the upper arm cephalic vein,\n     2. the median cubital vein connecting to the upper arm basilic vein,\n     3. the perforator vein connecting to the deep venous system.\n   * Upper arm veins must show central continuity with no detectable occlusions.\n5. Palpable radial artery with a diameter of ≥ 2.0 mm at the site of proposed AVF creation without significant stenosis along the course\n6. Positive Allen's Test\n7. At least one patent internal jugular vein suitable for Amplifi Inflow Catheter insertion\n8. Subject has voluntarily signed written informed consent\n\nExclusion Criteria:\n\n1. Known allergy to Amplifi System components (polyurethane, nitinol), iodinated contrast agents, heparin, or apixaban\n2. Known or suspected active infection at the proposed time of Amplifi System placement\n3. Known bleeding diathesis, including from uncorrected coagulopathy\n4. Known thrombophilia, requiring treatment\n5. Hb \\\u003C7 gm\u002FdL\n6. Platelet level \\\u003C 100,000 \u002Fmm3\n7. Significant radial artery calcification\n8. Need for continued treatment with anti-platelet agents or other anticoagulants (other than apixaban) during the Amplifi System treatment period\n9. Known history of patent foramen ovale \\> 2 mm\n10. History of recent intracranial or gastrointestinal bleeding\n11. Documented recent central venous or right atrial thrombus\n12. Known presence or recent history of intracranial or gastrointestinal bleeding or presence of underlying conditions that would predispose to intracranial or internal bleeding. Documented recent central venous or right atrial thrombus\n13. History of recent ipsilateral central venous occlusion, stenosis \\> 50%, angioplasty, or stent placement\n14. Pregnancy, lactation, or plans to become pregnant during the Study\n15. Expected survival less than 12 months\n16. Unwillingness or inability to comply with procedures specified in the Protocol, or difficulty or inability to return for follow-up visits as specified by the Protocol\n17. Participation in any other investigational drug or medical device study that has not completed primary endpoint evaluation or clinically interferes with the endpoints from the Study, or planned future participation in such studies prior to the completion of the Study",{"count":128,"type":20},160,[61],"The AMPLIFI-1 Study is a prospective, multicenter pivotal clinical trial designed to evaluate the safety and effectiveness of the Amplifi™ Vein Dilation System in patients requiring distal arteriovenous fistula (AVF) creation for hemodialysis. The study has two cohorts: a randomized controlled (RC) cohort of patients with suitable cephalic veins (≥2.5 mm) randomized 2:1 to Amplifi treatment plus AVF creation versus standard AVF creation alone, and a non-randomized small vein cohort (NRC) of patients with borderline veins (1.7 to \\\u003C2.5 mm) treated with Amplifi therapy followed by AVF creation.",[28],[133],"Pre-vein dilation for AVF access","RECRUITING","2026-06-22",{"date":137,"type":42},"2026-06-23",{"date":139,"type":42},"2026-05-12",{"date":141,"type":20},"2027-12-01",{"name":143,"class":144},"Amplifi Vascular, Inc.","INDUSTRY",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":118},"100594271","phase-4-glucagon-like-peptide-1-receptor-agonists-in-patients-receiving-maintenance-dialysis-100594271","NCT07017270","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","GUARD-1","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days\n3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and\u002For insulin.\n4. Ability to provided informed consent or through their substitute decision maker\n\nExclusion Criteria:\n\n1. Type 1 DM\n2. Use of a GLP-1-RA within 30 days prior to screening\n3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)\n4. Confirmed pregnancy, women of childbearing potential\n5. Known hypersensitivity to GLP-1-RA\n6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months\n7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA",{"count":153,"type":20},100,[155],"PHASE4","This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.",[158,159,160,28],"Kidney Disease, Chronic","Diabetes","Dialysis",[160,162,163,33,164,165],"Type 2 diabetes","semaglutide","GLP1","GLP1RA",{"date":167,"type":42},"2026-06-26",{"date":169,"type":42},"2025-11-27",{"date":171,"type":20},"2027-09",{"name":48,"class":49},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":80},"100619021","preoperative-hemodialysis-timing-in-patients-with-end-stage-kidney-disease-the-pod-eskd-pilot-trial-100619021","NCT07339202","Preoperative Hemodialysis Timing in Patients With End-Stage Kidney Disease: The POD-ESKD Pilot Trial","POD-ESKD","Inclusion Criteria:\n\n1. Patient is willing to comply with all study procedures for the duration of the study\n2. Patient has a diagnosis of ESKD\n3. Patient initiated hemodialysis at least 90 days prior to the planned surgical procedure\n4. Patient is treated with a stable hemodialysis schedule, defined as an average of 2.5- 3.5 hemodialysis sessions per week in the preceding 4 weeks prior to surgery\n5. Patient is scheduled to undergo nonemergent surgical procedures in the Stanford Health Care system. This includes (but is not limited to):\n\n   * Fistula or graft creation, revision, or removal\n   * Fistulogram\n   * Peritoneal dialysis catheter placement or revision\n   * Lower extremity angiogram (including femoral and iliac vessels)\n   * Lower extremity bypass (including femoral and iliac vessels)\n   * Lower extremity amputation\n   * Lower extremity endarterectomy (including femoral and iliac vessels) Of note, this list of procedures is not exhaustive and other procedures may be considered that meet inclusion criteria and no exclusion criteria, in consultation with the treatment teams involved.\n\nExclusion Criteria:\n\n1. Patient is pregnant\n2. Patient is a prisoner\n3. Patient is \\\u003C 18 years old\n4. The treating clinicians determine that the patient's clinical condition necessitate a specific approach to surgical scheduling or preoperative hemodialysis",{"count":90,"type":20},[61],"The goal of this clinical trial is to evaluate the feasibility of two different preoperative hemodialysis schedules for people with end-stage kidney disease (ESKD) who undergo surgical procedures. The main questions it aims to answer are:\n\nIs it feasible to randomize participants with ESKD undergoing nonemergent surgical procedures to same-day hemodialysis versus no same-day hemodialysis?\n\nIs it safe to randomize participants with ESKD undergoing nonemergent surgical procedures to same-day hemodialysis versus no same-day hemodialysis?\n\nResearchers will compare the two hemodialysis schedules to see if the scheduling and safety profiles are the same.\n\nParticipants will:\n\nAnswer questions about their health up to 4 weeks before and 4 weeks after the surgical procedure.\n\nReceive hemodialysis on the day of the surgical procedure or not, depending on the study treatment assignment.",[184,28,98],"Perioperative Management","2026-06-08",{"date":187,"type":42},"2026-06-11",{"date":189,"type":42},"2026-05-27",{"date":191,"type":20},"2027-10-15",{"name":193,"class":49},"Stanford University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":80},"100635671","stargraft-10401-pilot-100635671","NCT07555717","STARgraft (10401) Pilot","STARgraft Vascular Graft 10401 for Hemodialysis Access Pilot","Inclusion Criteria:\n\n1. Adult patients, 18 years or older.\n2. Patient has given informed consent to participate in the trial.\n3. Stated willingness to comply with all trial procedures and availability for the duration of the trial.\n4. Able to effectively communicate with trial personnel.\n5. Indicated patient population (end stage renal disease).\n6. Candidate for a new AV graft placed in the upper arm and judged to need dialysis within 2 months. Patient may have a failed access at a different anatomical location.\n7. Life expectancy judged to be at least 2 years with consideration of patient frailty.\n8. Axillary vein approximately 7 mm in diameter or greater.\n9. Brachial artery approximately 4 mm in diameter or greater.\n10. Acceptable cardiac risk level (cardiac output ≥ 3.5 l\u002Fmin, pulmonary artery pressure ≤ 50 mmHg, and ejection fraction ≥ 40%).\n11. Systolic blood pressure equal to or greater than 120 mmHg.\n12. Absence of central venous stenosis downstream from implant site confirmed with ultrasound and\u002For venogram.\n\nExclusion Criteria:\n\n1. Unable or unlikely to comply with trial protocol and\u002For follow-up.\n2. Pregnancy.\n3. Previous history of Peritoneal Dialysis treatment within the last 2 months\n4. Central venous catheter located on same side as intended implant location.\n5. Clinical morbid obesity (BMI \\> 40).\n6. Anatomical limitations, including issues discovered intraoperatively during vessel exposure.\n7. Immunodeficiency syndrome.\n8. History of hypercoagulation or bleeding disorders.\n9. Elevated platelet count \\> 1 million per microliter of blood.\n10. History of heparin-induced thrombocytopenia syndrome\n11. Medically confirmed stenosis or compromised valves in the veins downstream of the implant site.\n12. Inadequate arterial flow or pressure proximal to the implant site.\n13. Currently participating in another investigational drug or device trial which may clinically interfere with any endpoints of this trial.\n14. Fever greater than 38°C.\n15. Known allergic reaction to silicone, or untreatable allergy to imaging contrast materials.\n16. Confirmed or suspected bacterial, viral or parasitic infection within 8 weeks prior to graft implant, or ongoing symptoms.\n17. Uncontrolled or poorly controlled diabetes.\n18. History or evidence of severe cardiac disease.\n19. Any other condition which, in the judgment of the Investigator, would preclude adequate evaluation or impact patient safety or trial conduct.",{"count":202,"type":20},20,[61],"This study is a single site, prospective, single arm evaluation of the safety and effectiveness of the Healionics STARgraft (10401) hemodialysis access graft.\n\nThe study is enrolling patients with End Stage Renal Disease (ESRD) requiring hemodialysis via a prosthetic vascular graft. The study proposes to evaluate the performance of the investigational STARgraft (10401) compared to the ePTFE controls in a prior study (NCT03916731) and to published results, over a period of 6 months. Additional data out to 36 months post-implantation may be captured.",[28],[98,107,207],"Arterio-venous Grafts (AVG)","2026-04-21",{"date":210,"type":42},"2026-04-29",{"date":212,"type":42},"2026-01-29",{"date":214,"type":20},"2028-12",{"name":216,"class":144},"Healionics Corporation",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":225,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":228,"conditions":229,"keywords":232,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100597551","sensor-based-congestion-alert-for-events-in-peritoneal-dialysis-scale-pd-100597551","NCT07059962","Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)","Sensor-based Congestion Alert for Events in Peritoneal Dialysis (SCALE-PD)","SCALE-PD","Inclusion Criteria:\n\n1. Age 21 years or older\n2. Able to speak and read English, or able to speak and read Spanish and has a caregiver or family member who speaks English and can provide assistance\n3. Able to stand on two bare feet unassisted\n4. Receiving automated peritoneal dialysis for the treatment of ESKD\n5. Followed on the Vantive Sharesource Remote Patient Management Platform\n\nExclusion Criteria:\n\n1. Undergoing or plan to undergo hemodialysis in the next 12 months\n2. Have a life expectancy of less than 12 months\n3. Are pregnant or plan to become pregnant during the next 12 months\n4. Weigh greater than 375 lbs\n5. Planned kidney transplant within the next 12 months\n6. Have an implanted neurostimulator system","21 Years",{"count":227,"type":20},125,"To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.",[230,231,28],"Kidney Disease","Peritoneal Dialysis (PD)",[233,234,235,236],"kidney disease","peritoneal dialysis","fluid overload","heart failure","2026-03-17",{"date":239,"type":42},"2026-03-18",{"date":241,"type":42},"2025-09-09",{"date":243,"type":20},"2026-06",{"name":245,"class":144},"Bodyport Inc.",4,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":255,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":80},"100605044","effect-of-a-plant-focused-diet-on-nutritional-status-in-malnourished-peritoneal-dialysis-patients-100605044","NCT07157397","Effect of a Plant-Focused Diet on Nutritional Status in Malnourished Peritoneal Dialysis Patients","Effect of Plant-Focused Diet on Nutritional Status of Malnourished Patients Undergoing Peritoneal Dialysis in a Selected Hospital Care Setting","Inclusion Criteria:\n\n* Adult outpatients (\\>18 years old), attending HTCM PD clinic visits\n* Have undergone peritoneal dialysis for at least 6 months\n* Have a serum albumin level \\\u003C40 g\u002FL\n* Have a BMI of \\\u003C 25 kg\u002Fm2\n* Have a malnutrition inflammation score (MIS) of mild, moderate or severe\n* Agreed to follow the dietary instructions based on the randomization assignment\n* Agreed to attend baseline visits and additional follow-up appointments at months 1, 3, and 6 post- randomization, either in person or via telehealth, and respond to monthly or more frequent phone calls\n\nExclusion Criteria:\n\n* Have been hospitalized for the past 3 months\n* Have ongoing infection\u002Fsepsis\n* Has undergone surgery in the past 6 months\n* Have high inflammatory diseases, malignancy, or cancer\n* Have dialysis adequacy of \\\u003C1.2 Kt\u002FV",{"count":153,"type":20},[61],"The goal of this clinical trial is to determine whether a plant-focused diet improves nutritional and health outcomes of malnourished adults undergoing peritoneal dialysis (PD). It will also learn about the safety of this diet in this population.\n\nThe main questions it aims to answer are:\n\n1. Does a plant-focused diet improve nutritional status compared to a standard kidney diet in PD patients?\n2. What changes occur in anthropometric, biochemical, and dietary measures over 6 months?\n\nResearchers will compare the plant-focused diet to a standard-of-care renal diet to see which is more effective in improving nutrition in PD patients.\n\nParticipants will:\n\n* Be randomly assigned to follow the plant-focused diet or the standard diet.\n* Be monitored for 6 months through in-person visits (aligned with their routine clinic appointments) and virtual check-ins via messages or calls.\n* Have their progress monitored for changes in outcomes such as nutrition, blood tests, kidney function, and quality of life.",[258,28,231,259],"End Stage Renal Disease (ESRD)","Malnourished",[261,262,70,263,264,265,266,267,268,269,270,271,272,273],"Peritoneal Dialysis","End Stage Renal Disease","Malnutrition","Plant-Focused Diet","Plant-Based Diet","Nutritonal Status","Dietary Counselling","Quality of Life","Physical Fitness","Inflammation","Appetite","Malaysia","Nutritional Intervention","2026-03-12",{"date":276,"type":42},"2026-03-16",{"date":278,"type":42},"2026-03-10",{"date":280,"type":20},"2027-03-31",{"name":282,"class":49},"National University of Malaysia",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":291,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":21,"phases":293,"briefSummary":294,"conditions":295,"keywords":302,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":4},"100625231","older-kidney-patient-optimisation-pretransplant-100625231","NCT07419945","Older Kidney Patient Optimisation Pretransplant","Optimising Access to and Outcomes From Transplantation in Older Potential Kidney Transplant Recipients: Pilot Feasibility Study on Kidney Transplant-specific Comprehensive Geriatric Assessment (KT-CGA)","OK-POP","Inclusion Criteria:\n\n* Adults aged 60 years or older\n* Attending Guy's and St Thomas' (GSTT) Nephrology services\n* Diagnosed with Chronic Kidney Disease (CKD) Stage 5\n\nEither:\n\n* Pre-dialysis, or\n* Receiving dialysis (in-centre haemodialysis, peritoneal dialysis, or home haemodialysis)\n* Referred to the kidney transplant surgical clinic for assessment of suitability for kidney transplantation (pre-transplant evaluation)\n\nExclusion Criteria:\n\n* Adults aged under 60 years\n* Patients currently attending the Nephrology Supportive Care service at GSTT","60 Years",{"count":59,"type":20},[61],"The goal of this clinical trial is to learn if a kidney transplant-specific comprehensive geriatric assessment (KT-CGA) can improve the way older adults are assessed for kidney transplantation. The main questions it aims to answer are:\n\nIs it feasible and acceptable to deliver a KT-CGA alongside routine transplant assessment in older adults with advanced kidney disease?\n\nWhat is the effect of KT-CGA on decision-making about transplant listing and on patient-reported outcomes such as quality of life and frailty?\n\nResearchers will compare participants who receive the KT-CGA plus usual care to those who receive usual care alone.\n\nParticipants will:\n\nContinue with their usual transplant assessment process\n\nIf randomised to the intervention group, also complete the KT-CGA (a structured set of questionnaires, short memory and function tests, and discussions about wellbeing and support needs, taking about 45-60 minutes)",[230,296,297,298,299,28,300,301],"Kidney Failure","Frailty","Cognitive Impairment","Multimorbidity","Kidney Transplant","Health Inequity",[303,304,305,306,33,307],"kidney transplant","frailty","multimorbidity","cognitive impairment","health inequality","2026-02-12",{"date":310,"type":42},"2026-02-19",{"date":312,"type":20},"2026-02-02",{"date":314,"type":20},"2028-02-02",{"name":316,"class":49},"Guy's and St Thomas' NHS Foundation Trust",{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":21,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":80},"100613809","phase-4-blood-pressure-control-with-thiazide-diuretics-in-peritoneal-dialysis-patients-100613809","NCT07271420","Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients","Inclusion Criteria:\n\n* Patients on chronic peritoneal dialysis, with uncontrolled hypertension (SBP \\>140 mmHg and\u002For DBP \\>90 mmHg)\n\nExclusion Criteria:\n\n* Patients with a life expectancy of less than 3 months, planned conversion to hemodialysis, or scheduled kidney transplantation within 3 months",{"count":324,"type":20},40,[155],"To evaluate the blood pressure lowering effects of thiazide diuretics in patients on peritoneal dialysis",[328,261,28],"Hypertension",[328,330,331,332],"Thiazides diuretics","End stage kidney disease","Peritoneal dialysis","2025-11-26",{"date":335,"type":42},"2025-12-09",{"date":337,"type":42},"2020-01-01",{"date":339,"type":20},"2027-06-30",{"name":341,"class":49},"Chinese University of Hong Kong",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":21,"phases":350,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":80},"100592166","comparing-super-high-flux-and-high-flux-dialyzer-performance-among-hemodialysis-patient-with-sepsis--a-randomized-control-trial-100592166","NCT06989892","Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial","Inclusion Criteria:\n\n* ESKD patients who have sepsis condition with high interleukin-6 (IL-6 \\> 50 pg\u002Fml)\n\nExclusion Criteria:\n\n* Patients who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who expected to pass away within the 24 hours.\n* Patients who have the history of allergic dialyzer reaction to dialyzer which used in this trial.",{"count":349,"type":20},202,[61],"Comparing the efficacy of superhigh-flux dialyzer with high-flux dialyzer in ESKD patient who have sepsis to improve mortality and sepsis outcome, an open label randomized control trial.",[353,28,354],"The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD","Sepsis",[356,357,33,358],"Superhighflux","hemodialysis","sepsis","2025-05-19",{"date":361,"type":42},"2025-05-25",{"date":363,"type":42},"2024-07-25",{"date":365,"type":20},"2026-10-01",{"name":367,"class":49},"Navamindradhiraj University"]